Skip to main content
SpringerLink
Log in

Role of Estramustine Phosphate and Other Estrogens for Castration-Resistant Prostate Cancer

  • Chapter
  • First Online:
Hormone Therapy and Castration Resistance of Prostate Cancer

Abstract

The introduction of several expensive drugs, as abiraterone acetate and enzalutamide, and expansion of indication of these new drugs for prostate cancer patients resulted in dramatic increase in cancer treatment costs for castration-resistant prostate cancer. Estramustine phosphate and other estrogens such as ethinylestradiol are far less costly and might offer significant advantages over some of the new castration-resistant prostate cancer treatment, especially regarding bone health, cognition, and metabolic status for prostate cancer patients. Herein we discussed about mechanisms of estramustine phosphate and estrogen compounds for prostate cancer. Moreover, we reviewed several reports of efficacy of treatment with estramustine phosphate and other estrogens for castration-resistant prostate cancer. Furthermore, beneficial effects of estrogen compounds in comparison to luteinizing hormone-releasing hormone agonists during treatment for prostate cancer patients were discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7.

    CAS  Google Scholar 

  2. Bailar JC 3rd, Byar DP. Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo. Cancer. 1970;26:257–61.

    Article  PubMed  Google Scholar 

  3. Ockrim J, Lalani El N, Abel P. Therapy insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy. Nat Clin Pract Oncol. 2006;3:552–63.

    Article  CAS  PubMed  Google Scholar 

  4. Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol. 1995;154:1991–8.

    Article  CAS  PubMed  Google Scholar 

  5. Hartley-Asp B, Deinum J, Wallin M. Diethylstilbestrol induces metaphase arrest and inhibits microtubule assembly. Mutat Res. 1985;143:231–5.

    Article  CAS  PubMed  Google Scholar 

  6. Robertson CN, Roberson KM, Padilla GM, O’brien ET, Cook JM, Kim CS, Fine RL. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst. 1996;88:908–17.

    Article  CAS  PubMed  Google Scholar 

  7. Schulz P, Link TA, Chaudhuri L, Fittler F. Role of the mitochondrial bc1-complex in the cytotoxic action of diethylstilbestrol-diphosphate toward prostatic carcinoma cells. Cancer Res. 1990;50:5008–12.

    CAS  PubMed  Google Scholar 

  8. Kitahara S, Umeda H, Yano M, Koga F, Sumi S, Moriguchi H, Hosoya Y, Honda M, Yoshida K. Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer. Endocr J. 1999;46:659–64.

    Article  CAS  PubMed  Google Scholar 

  9. Saha P, Debnath C, Berube G. Steroid-linked nitrogen mustards as potential anticancer therapeutics: a review. J Steroid Biochem Mol Biol. 2013;137:271–300.

    Article  CAS  PubMed  Google Scholar 

  10. Walz PH, Bjork P, Gunnarsson PO, Edman K, Hartley-Asp B. Differential uptake of estramustine phosphate metabolites and its correlation with the levels of estramustine binding protein in prostate tumor tissue. Clin Cancer Res. 1998;4:2079–84.

    CAS  PubMed  Google Scholar 

  11. Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol. 1997;15:13–9.

    CAS  PubMed  Google Scholar 

  12. Eklov S, Nilsson S, Larson A, Bjork P, Hartley-Asp B. Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo. Prostate. 1992;20:43–50.

    Article  CAS  PubMed  Google Scholar 

  13. Hartley-Asp B. Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. Prostate. 1984;5:93–100.

    Article  CAS  PubMed  Google Scholar 

  14. Laing N, Dahllof B, Hartley-Asp B, Ranganathan S, Tew KD. Interaction of estramustine with tubulin isotypes. Biochemistry. 1997;36:871–8.

    Article  CAS  PubMed  Google Scholar 

  15. Panda D, Miller HP, Islam K, Wilson L. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc Natl Acad Sci U S A. 1997;94:10560–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Pienta KJ, Lehr JE. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol. 1993;149:1622–5.

    Article  CAS  PubMed  Google Scholar 

  17. Norlen BJ, Andersson SB, Bjork P, Gunnarsson PO, Fritjofsson A. Uptake of estramustine phosphate (estracyt) metabolites in prostatic cancer. J Urol. 1988;140:1058–62.

    Article  CAS  PubMed  Google Scholar 

  18. Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol. 1994;12:2005–12.

    Article  CAS  PubMed  Google Scholar 

  19. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin M, Burch P, Berry D, Moinpour C, Kohli M, Benson M, Small E, Raghavan D, Crawford E. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.

    Article  CAS  PubMed  Google Scholar 

  20. Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S, Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists’ Collaborative Group. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol. 2007;8:994–1000.

    Article  CAS  PubMed  Google Scholar 

  21. Qin Z, Li X, zhang J, Tang J, Han P, Xu Z, Yu Y, Yang C, Wang C, Xu T, Xu Z, Zou Q. Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95:e4801.

    Article  CAS  Google Scholar 

  22. Hirano D, Minei S, Kishimoto Y, Yamaguchi K, Hachiya T, Yoshida T, Yoshikawa T, Endoh M, Yamanaka Y, Yamamoto T, Satoh Y, Ishida H, Okada K, Takimoto Y. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. Urol Int. 2005;75:43–9.

    Article  CAS  PubMed  Google Scholar 

  23. Inoue T, Ogura K, Kawakita M, Tsukino H, Akamatsu S, Yamasaki T, Matsui Y, Segawa T, Sugino Y, Kamoto T, Kamba T, Tanaka S, Ogawa O. Effective and safe administration of low-dose estramustine phosphate for castration-resistant prostate cancer. Clin Genitourin Cancer. 2016;14:e9–e17.

    Article  PubMed  Google Scholar 

  24. Matsumoto K, Tanaka N, Hayakawa N, Ezaki T, Suzuki K, Maeda T, Ninomiya A, Nakamura S. Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature. Med Oncol. 2013;30:717.

    Article  PubMed  Google Scholar 

  25. Minato A, Fujimoto N, Kubo T, Harada S, Akasaka S, Matsumoto T. Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer. Med Oncol. 2012;29:2895–900.

    Article  CAS  PubMed  Google Scholar 

  26. Naiki T, Okamura T, Kawai N, Sakagami H, Yamada Y, Fujita K, Akita H, Hashimoto Y, Tozawa K, Kohri K. Advantages of second line estramustine for overall survival of hormone-refractory prostate cancer (HRPC) patients. Asian Pac J Cancer Prev. 2009;10:71–4.

    PubMed  Google Scholar 

  27. Ravery V, Fizazi K, Oudard S, Drouet L, Eymard JC, Culine S, Gravis G, Hennequin C, Zerbib M. The use of estramustine phosphate in the modern management of advanced prostate cancer. BJU Int. 2011;108:1782–6.

    Article  CAS  PubMed  Google Scholar 

  28. Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med. 2016;5:182–91.

    Article  PubMed  Google Scholar 

  29. Petrioli R, Roviello G, Fiaschi AI, Laera L, Bianco V, Ponchietti R, Barbanti G, Francini E. Low-dose Estramustine phosphate and concomitant low-dose acetylsalicylic acid in heavily pretreated patients with advanced castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13:441–6.

    Article  PubMed  Google Scholar 

  30. Wilkins A, Shahidi M, Parker C, Gunapala R, Thomas K, Huddart R, Horwich A, Dearnaley D. Diethylstilbestrol in castration-resistant prostate cancer. BJU Int. 2012;110:E727–35.

    Article  CAS  PubMed  Google Scholar 

  31. Turo R, Tan K, Thygesen H, Sundaram SK, Chahal R, Prescott S, Cross WR. Diethylstilboestrol (1 mg) in the management of castration-resistant prostate cancer. Urol Int. 2015;94:307–12.

    Article  CAS  PubMed  Google Scholar 

  32. Sciarra A, Gentile V, Cattarino S, Gentilucci A, Alfarone A, D’eramo G, Salciccia S. Oral ethinylestradiol in castration-resistant prostate cancer: a 10-year experience. Int J Urol. 2015;22:98–103.

    Article  CAS  PubMed  Google Scholar 

  33. Izumi K, Kadono Y, Shima T, Konaka H, Mizokami A, Koh E, Namiki M. Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients. Anticancer Res. 2010;30:5201–5.

    CAS  PubMed  Google Scholar 

  34. Onishi T, Shibahara T, Masui S, Sugino Y, Higashi S, Sasaki T. Efficacy of Ethinylestradiol re-challenge for metastatic castration-resistant prostate cancer. Anticancer Res. 2016;36:2999–3004.

    CAS  PubMed  Google Scholar 

  35. Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, de Porre P, Todd MB, Yu MK, Ryan CJ. Clinical outcomes from androgen signaling-directed therapy after treatment with Abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. Eur Urol. 2017;72:10–3.

    Article  CAS  PubMed  Google Scholar 

  36. Langley RE, Cafferty FH, Alhasso AA, Rosen SD, Sundaram SK, Freeman SC, Pollock P, Jinks RC, Godsland IF, Kockelbergh R, Clarke NW, Kynaston HG, Parmar MK, Abel PD. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol. 2013;14:306–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Gilbert DC, Duong T, Kynaston HG, Alhasso AA, Cafferty FH, Rosen SD, Kanaga-Sundaram S, Dixit S, Laniado M, Madaan S, Collins G, Pope A, Welland A, Nankivell M, Wassersug R, Parmar MK, Langley RE, Abel PD. Quality-of-life outcomes from the prostate adenocarcinoma: TransCutaneous hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. BJU Int. 2017;119:667–75.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Takahiro Inoue M.D., Ph.D.

Authors
  1. Takahiro Inoue M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takahiro Inoue M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Urology, Tohoku University School of Medicine, Sendai, Japan

    Yoichi Arai

  2. Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Osamu Ogawa

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Inoue, T. (2018). Role of Estramustine Phosphate and Other Estrogens for Castration-Resistant Prostate Cancer. In: Arai, Y., Ogawa, O. (eds) Hormone Therapy and Castration Resistance of Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-7013-6_26

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-7013-6_26

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-7012-9

  • Online ISBN: 978-981-10-7013-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation